Normalizing Serologies Enhances Remission in SLE Analysis of five phase III belimumab (BEL) trials reveals that normalizing serologies affords protection against severe and renal SLE flares, supporting the concept of treat-to-target to minimize risk in SLE.… https://t.co/eW9EUyvts7 https://t.co/OdM0WkLtjd

Intraarticular Steroids in OA Lowers Need for Pain Meds Is it possible that intra-articular corticosteroid injections for osteoarthritis might affect the use of opioids? https://t.co/pw6vWbFRQx https://t.co/5KrB9uJv7M

Genentech announced that FDA has accepted a Supplemental Biologics License Application for obinutuzumab (anti-CD20 mAb; Gazyva) for the Treatment of Lupus Nephritis based on positive results from Phase III REGENCY study. FDA decision by October 2025 https://t.co/Mx3YDUfkMg https://t.co/MTBZo1TCrK

Sleep disturbance increases disability progression - Prospective cohort data from from 70K Nurses’ Health Study w/ 392 having MS, 7,302 DM, & 25K OA. Having Sleep apnea or disturbances signif incr disability in OA & DM (OR~1.4) as was excessive daytime sleepiness… https://t.co/5PP18gqDqi https://t.co/u1HFOstv8W

FDA grants priority reviews to: - Nicalizumab (J&J; FcRn antibody) for use in Myasthenia gravis. - Upadacitinib (AbbVie; JAK inhib) for use in GCA - Namistat (BI: PDE4B inhib) for use in Idiopathic pulmonary fibrosis - Inalizumab (Hansen; anti-CD19) for use in IG4 rel Dz -… https://t.co/dsg9vZASrk https://t.co/8t2USASmm8

SOCS1 Insufficiency - a Rare Inborn Error of Immunity Lancet Rheumatology has published a population study of the rare suppressor of cytokine signalling 1 (SOCS1) insufficiency - an inborn error of immunity affecting the negative regulation of cytokine and growth factor… https://t.co/I0muoIk5GL https://t.co/jbcuAZivci

Early Hydroxychloroquine Slows Cutaneous Lupus Progression A prospective study of patients with limited cutaneous lupus erythematosus (CLE) shows that early introduction of hydroxychloroquine (HCQ) may prevent progression to systemic lupus erythematosus (SLE).… https://t.co/cxz4DJ6AUs https://t.co/FlgwykFnfl

RheumNow Live 2025 is now available On Demand For the first time, https://t.co/4UQlqwujiR is offering exclusive access to: ✅ 7 STEP Talks from top rheumatology experts ✅ 21 Powerful lectures and Q & A Panels answering real-world questions ✅ All speaker slides and handouts… https://t.co/HokIfxbgTd https://t.co/ztVymFLuRT

From Bellyache to Bloodstorm - a Mesenteric Sclerosis case with Macrophage Activation Syndrome Presentation by Dr. Anjali Nidhaan at the Rheumatology Winter Clinical Symposia - Feb 2025 https://t.co/pXwav5f2BI https://t.co/0Faao7zhbV

Full read review of Hydryoxychloroquine -its pharmacology, MOA (eg, blocking TLR 7 & 9), Dz specific efficacy and adverse effects https://t.co/WVErW1RrCj https://t.co/eQVFIZNSRx

Bubble Trouble - When Bullous Lupus Bursts onto the SLE Scene Presentation by Dr. Alana Haussmann at the Rheumatology Winter Clinical Symposia - Feb 2025 https://t.co/LRsT1TLEm4 https://t.co/bSi50pDn2O